Robineau, O.
Talagrand-Reboulh, E.
Brunschweiler, B.
Jehl, F.
Beltrand, E.
Rousseau, F.
Blondiaux, N.
Grillon, A.
Joseph, C.
Lambotte, P.
Boyer, P.
Senneville, Eric http://orcid.org/0000-0002-5720-8908
,
Funding for this research was provided by:
no funding source
Article History
Received: 17 March 2021
Accepted: 10 May 2021
First Online: 20 May 2021
Declarations
:
: The study was recorded in ExternalRef removed under the number NCT02860767, in the EudraCT database under the number 2013-000889-11 and was approved by the ExternalRef removed and Health Products’ Safety on 27 October 2015 and by the French Nord-Ouest IV <i>Committee</i> of <i>Protection</i> of the <i>People</i> in Biomedical Research on 8 March 2016<i>.</i>
: All patients gave their written consent to participate in the study.
: ES and FJ declare congress support, speaker invitation, and participation to scientific board with Novartis Pharma; OR declares speaker invitation and participation to scientific board with Gilead, ViiV, and MSD. Other co-authors do not declare any potential conflict of interest in relation with the present study.